Equibles does not estimate personal net worth.
Get an email with a short summary when Fulgent Genetics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FLGT alertsMing Hsieh is recorded as CEO at Fulgent Genetics, Inc. (FLGT). The newest filing on record that lists Ming Hsieh as CEO at Fulgent Genetics, Inc. (FLGT) is dated March 31, 2026. Fulgent Genetics, Inc. reported in an 8-K filed May 14, 2026 that Ming Hsieh was appointed director, effective May 14, 2026. The proxy statement of Fulgent Genetics, Inc. reports total compensation of $6,207,000 for Ming Hsieh in fiscal 2025, including a base salary of $1,000,000. Disclosed compensation is on record for 8 fiscal years. Ming Hsieh has spoken on 27 earnings calls across 1 company, most recently for Fulgent Genetics, Inc. on November 5, 2026. Fulgent Genetics, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Fulgent Genetics, Inc. includes Paul Kim (CFO), Jian Xie (COO), Hanlin Gao (Board Member) and 5 others.
“Election of the following nominees as directors of the Company, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.”
“I will start with some comments on our two business ones. Then, Brandon will reveal our product and go-to-market updates for our laboratory service business. And Paul will conclude with the financials and outlook before we take your questions.”
“I will start with some comments on our two business lines, then Brandon will review our product and go to market update for our laboratory service business. And Paul will conclude with the financial and audit before we take your questions.”
“I will start with some comments on our two business lines. Then Brandon will review our product and go-to-market updates for our laboratory service business. And Paul will conclude with financials and outlook before we take your questions.”
“I'm pleased with the progress we have made this year as we execute our strategic objectives in both our laboratory services and the therapeutic development business.”
“I will start with some comments on the third quarter of 2025 and our two business lines. Then Brandon will review our product and go-to-market updates for our laboratory services business.”
Start not stated–present
Last confirmed March 31, 2026
Start not stated–2021-04-01
Last confirmed by a filing; no departure on record
Diagnostics & Research · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Fulgent Genetics, Inc. (FLGT) | Chief Executive Officer | $1,000,000 | $6,207,000 |
| 2024 | Fulgent Genetics, Inc. (FLGT) | Chief Executive Officer | $1,000,000 | $6,128,000 |
| 2023 | Fulgent Genetics, Inc. (FLGT) | Chief Executive Officer | $1,000,000 | $5,309,167 |
| 2022 | Fulgent Genetics, Inc. (FLGT) | Chief Executive Officer | $947,917 | $5,233,873 |
| 2021 | Fulgent Genetics, Inc. (FLGT) | Chief Executive Officer | $664,303 | $5,664,303 |
| 2020 | Fulgent Genetics, Inc. (FLGT) | Chief Executive Officer | $240,000 | $248,000 |
| 2019 | Fulgent Genetics, Inc. (FLGT) | President and Chief Executive Officer | $240,000 | $240,000 |
| 2018 | Fulgent Genetics, Inc. (FLGT) | President and Chief Executive Officer | $240,000 | $240,000 |
